A simple model for the total number of SARS-CoV-2 infections on a national level

N. Blanco1, K. A. Stafford1,2, M. C. Lavoie1, A. Brandenburg3, M. W. Górna4 and M. Merski4

1Center for International Health, Education, and Biosecurity, Institute of Human Virology-University of Maryland School of Medicine, Baltimore, Maryland, USA; 2Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA; 3Nordita, KTH Royal Institute of Technology and Stockholm University, SE-10691, Stockholm, Sweden and 4Structural Biology Group, Biological and Chemical Research Centre, Department of Chemistry, University of Warsaw, Warsaw, Poland

Abstract

This study aimed to identify an appropriate simple mathematical model to fit the number of coronavirus disease 2019 (COVID-19) cases at the national level for the early portion of the pandemic, before significant public health interventions could be enacted. The total number of cases for the COVID-19 epidemic over time in 28 countries was analysed and fit to several simple rate models. The resulting model parameters were used to extrapolate projections for more recent data. While the Gompertz growth model (mean $R^2 = 0.998$) best fit the current data, uncertainties in the eventual case limit introduced significant model errors. However, the quadratic rate model (mean $R^2 = 0.992$) fit the current data best for 25 (89%) countries as determined by $R^2$ values of the remaining models. Projection to the future using the simple quadratic model accurately forecast the number of future total number of cases 50% of the time up to 10 days in advance. Extrapolation to the future with the simple exponential model significantly over-predicted the total number of future cases. These results demonstrate that accurate future predictions of the case load in a given country can be made using this very simple model.

Introduction

On 11 March 2020 the World Health Organization (WHO) declared the novel coronavirus outbreak (severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19)) a pandemic [1] more than three months after the first cases of pneumonia were reported in Wuhan, China in December 2019 [1]. From Wuhan the virus rapidly spread globally, currently leading to tens of millions of confirmed cases and over a million deaths around the world. Although coronaviruses have a wide range of hosts and cause disease in many animals, SARS-CoV-2 is the seventh named member of the Coronaviridae known to infect humans [2]. An infected individual will start presenting symptoms an average of five days after exposure [3] but it has been reported that 42% of infected individuals remain asymptomatic [4, 5]. In early November 2020, 2.5% people officially diagnosed with COVID-19 had died [6] while treatment and vaccine options for COVID-19 were limited [7]. A report from April 2020 noted 78 active vaccine projects, and some of the more recent results are quite promising with a number of vaccines being widely deployed in early 2021, although full worldwide distribution will likely still take several years [8–10]. Fortunately, aggressive contact tracing [11] and social isolation methods [7, 12, 13] as well as pharmaceutical interventions such as the steroid dexamethasone [14] and convalescent plasma [15] have shown some efficacy against the disease. As the virus is transmitted mainly from person to person, prevention measures include social distancing, self-isolation, hand washing and use of masks. Strict measures of quarantine have been shown to be the currently most effective mitigation measures, reducing up to 78% of expected cases compared to no intervention [12]. Nevertheless, to evaluate the actual effectiveness of any mitigation measure it is necessary to accurately predict the expected number of cases in the absence of intervention as an accurate number will better inform decisions about relaxing the mitigation measures which can be both economically and politically costly.

While there has been some early concern about the ability of SARS-CoV-2 to spread at an apparent near exponential rate [16, 17], limitations in available resources (i.e. susceptible population, sub-optimal mixing of infected and susceptible populations [18] etc.) will reduce the spread of any real (non-theoretical) disease to a logistic (sub-exponential) growth rate [19]. Logistic growth produces a sigmoidal curve over time (Fig. 1) where the total number of cases ($N$) eventually (barring new births [20]) asymptotically approaches the population carrying capacity ($N_{sa}$), which for viral epidemics is analogous to the fraction of the population that will be infected before ‘herd immunity’ is achieved.
Fig. 1. Illustrative comparison of exponential, quadratic, generalised logistic and Gompertz growth curves. The Gompertz growth curve (Equation 4, solid black line) representing the progress of a theoretical epidemic for a disease with an arbitrarily chosen $R_0$ value of 3.4 ($r = 0.045$, $N_0 = 1$, $N_M = 70\%$, dotted line). The solid grey line is an equivalent logistic curve, note that while the midpoint for both logistic curves is the same, the Gompertz curve reaches the population carrying capacity more slowly, resulting in a long-tailed epidemic. The initial part of the Gompertz curve (including time points until 5% of the population has been infected) was fit to the simple exponential (red dashes), quadratic (blue dashes) and simple square (green dashes) models. It is apparent from these curves how quickly the exponential model is the same, the Gompertz curve reaches the population carrying capacity more slowly, resulting in a long-tailed epidemic. The initial part of the Gompertz curve (including time points until 5% of the population has been infected) was fit to the simple exponential (red dashes), quadratic (blue dashes) and simple square (green dashes) models. It is apparent from these curves how quickly the exponential model is replaced by the quadratic model more closely follows the Gompertz growth curve, evidenced by the smaller $\chi^2$ value for the quadratic fit in Table 1.

[21–23]. This is represented in derivative form by the generalised logistic function (Equation 1):

$$\frac{dN}{dt} = rN^\alpha \left[ 1 - \left( \frac{N}{N_M} \right)^\beta \right] ^\gamma$$

(1)

where $\alpha$, $\beta$ and $\gamma$ are the mathematical shape parameters that define the shape of the curve and $r$ is the general rate term, analogous to the standard epidemiological parameter, $R_0$ [22, 24]. For a logistic curve where $\alpha = \frac{1}{2}$ and $\beta = \gamma = 0$, one gets quadratic growth [25] with $N = (rt/2)^2$. For $\alpha = \frac{1}{2}$ and $\beta = \gamma = 1$, we have quadratic growth with saturation (Supplemental Appendix 1) while for $\alpha = \beta = \gamma = 1$, this equation can be re-arranged to quadratic form (Equation 2) [19] and integrated (Equation 3):

$$\frac{dN}{dt} = \frac{-rN^2}{N_M} + rN$$

(2)

$$N(t) = \frac{N_0N_M}{(N_M-N_0)e^{-rt}+N_0}$$

(3)

where $N_0$ represents the initial number of cases within the population. The shape parameters of logistic functions magnify the uncertainty in fitting these curves especially during the early part of the epidemic. These difficulties are further exacerbated by the additional uncertainty in estimation of $R_0$ for SARS-CoV-2, which is directly linked to the current uncertainty in the population carrying capacity $N_M$. And while the basic logistic function gives rise to a symmetrical sigmoidal curve, asymmetrical curves such as the Gompertz growth function (Equation 4) [26, 27]:

$$N(t) = N_0 e^{\ln(N_0/N_M)(1-e^{-rt})}$$

(4)

which emerges [19] from Equation 1 for $\alpha = \gamma = 1$, where $r$ is replaced by $\beta$, and $\beta$ approaches zero. For Gompertz growth, the rate of spread slows significantly after passing the mid-point resulting in long-tailed epidemics (Fig. 1).

Traditionally, the number of cases that will occur in an epidemic like COVID-19 is modelled with an SEIR model (Susceptible, Exposed, Infected, Recovered/Removal), in which the total population is divided into four categories: susceptible – those who can be infected, exposed – those who are in the incubation period but not yet able to transmit the virus to others, infectious – those who are capable of spreading disease to the susceptible population and recovered/removed – those who have finished the disease course and are not susceptible to re-infection or have died. For a typical epidemic, the ability for infectious individuals to spread the disease is proportional to the fraction of the population in the susceptible category. 'Herd immunity' [21, 22] and extinction of the epidemic occurs once a limiting fraction of the population has entered into the Recovered/Removed category [22]. However, barriers to transmission, either natural [28] or artificial (i.e. quarantines, vaccines) [22] can extinguish the epidemic before the community is fully infected. Artificial barriers such as mandatory quarantining in China [29, 30] or aggressive contact tracing in South Korea [11] seem to have largely stemmed the spread of SARS-CoV-2 during the early portion of the pandemic. Numerous political, social and material factors hamper the implementation of either of these responses in many other countries [13], but it should be possible to find alternative approaches which can be equally effective. For an epidemic as serious as COVID-19, it behooves medical, scientific and policy experts to determine as rapidly as possible which community responses are effective and achievable within different populations. However, predictive underestimation will dampen response efforts while overestimation of the expected number of cases will make neutral or even harmful responses appear incorrectly effective when those overestimated cases fail to occur. Thus, accurate prospective predictions (i.e. before knowing the actual outcome) are preferable to retrospective analysis in which effectiveness is gauged after the results of the prescriptive actions are known [31, 32].

This study aimed to evaluate if a simple model was able to correctly fit the total number of confirmed cases and if that could be used to extrapolate to the total number of cases at a future date [23]. We found that fitting the case data from the early portion of the pandemic to a quadratic (parabolic) rate curve [25] for the early days of the individual national epidemics was easy, efficient and able to accurately estimate the number of cases at future dates despite significant national variation in the start of the infection, mitigation response or economic condition.

Methods

Data on the number of COVID-19 cases was downloaded from the European Centre for Disease Prevention and Control (ECDC) on 1 June 2020 and 10 October 2020 [33]. Countries that had reported the highest numbers of cases in mid-March 2020 (and Russia) were chosen as the focus of our analysis to minimise statistical error due to small numbers (although we were able to get good fits to data in both Australia and Malaysia which had less than 5000 total cases before the effect of interventions had become obvious). The total number of cases for each country was calculated as a simple sum of that day plus all previous days including days before the start of the fitting curve. Days that were missing from the record were assigned values of zero. The early part of the curve was fit and statistical parameters
were generated using Prism 8 (GraphPad) using the method of least squares as implemented in the non-linear regression module using the program standard centred second-order polynomial (quadratic), exponential growth and the Gompertz growth model as defined by Prism 8, and a simple user-defined simple square model \( \left( N = A t^2 + C \right) \) where \( N \) is the total number of cases, \( A \) and \( C \) are the fitting constants and \( t \) is the number of days from the beginning of the epidemic curve. The beginning of the curve was defined manually from among the first days in which the number of cases began to increase regularly without interruption by any days with zero officially reported cases. Typically, this occurred when the country had reported less than 100 total cases. Model fitting used at least five days of data at a minimum. The specific starting fit day for each country is given in Figures 2 and 3. The early part of the curve was defined by manual examination looking for changes in the curve shape and later confirmed by \( R^2 \) values for the quadratic model (Fig. 2). Projections for the number of cases at the end of the fit were generated by fitting the total number of COVID-19 cases for each day starting with day 5 and then extrapolating the number of cases using the estimated model parameters to estimate the number of cases for the final day for which data were available at the time (1 June 2020) or to the last day before significant decrease in the \( R^2 \) value (\( R^2 < 0.95 \)) for the quadratic fit. Fit parameters for the Gompertz growth model were not used for projections if the fit itself was ambiguous. The incidence (number of new cases per day) was calculated by subtracting the total number of cases on the previous day, examined over several day intervals. Estimates of the total future accuracy of the four models was estimated by predicting forward by 60 days for each of the four models when compared to the actual reported number of total cases using the fit parameters calculated as above (in many cases beyond the original final day of 1 June 2020). A prediction was judged to be successful if the total number of cases was within the range calculated from the 95% confidence interval (CI) fit values. Successful predictions were given a scoring reward of one point divided by half the width of the prediction interval in cases, while unsuccessful predictions were given zero points (Fig. 3). Instances of when the Gompertz model failed to fit all the parameters for the estimate of total accuracy were given a score of zero for that day. The bias was calculated as the amount of over or under prediction compared to the actual number of cases. The width was calculated as the difference between the limits of the 95% CI and normalised to the actual number of cases for that day.

| Model          | Mean   | Std. Dev | Median   |
|----------------|--------|----------|----------|
| Quadratic* \( (N = 28) \) |         |          |          |
| \( R^2 \)     | 0.9917 | 0.0044   | 0.9930   |
| Sum of squares| \( 2.2 \times 10^{10} \)  | \( 1.06 \times 10^{11} \)  | \( 8.71 \times 10^7 \)  |
| Sy.x          | 5612.9 | 15 068.7 | 1250.0   |
| AICc          | 822.1  | 504.3    | 703.15   |
| Prediction error | \(-4839 \) | 104 721 | \(-1776 \) |
| Simple square \( (N = 28) \) |         |          |          |
| \( R^2 \)     | 0.9780 | 0.0159   | 0.9821   |
| Sum of squares| \( 4.47 \times 10^{10} \)  | \( 2.03 \times 10^{11} \)  | \( 1.74 \times 10^9 \)  |
| Sy.x          | 8572.1 | 21 235.6 | 1591.5   |
| AICc          | 871.6  | 535.2    | 737.9    |
| Prediction error | \(-31 663 \) | 75 958 | \(-3365 \) |
| Simple exponential \( (N = 28) \) |         |          |          |
| \( R^2 \)     | 0.9568 | 0.0215   | 0.9548   |
| Sum of squares| \( 1.03 \times 10^{11} \)  | \( 5.23 \times 10^{11} \)  | \( 4.67 \times 10^9 \)  |
| Sy.x          | 11 257.0 | 32 734.8 | 3067.0   |
| AICc          | 899.5  | 530.2    | 777.7    |
| Prediction error | \( 4.1 \times 10^{18} \) | \( 2.2 \times 10^{19} \) | \( 5.2 \times 10^7 \) |
| Gompertz growth \( (N = 26) \) |         |          |          |
| \( R^2 \)     | 0.9978 | 0.0028   | 0.9991   |
| Sum of squares| \( 2.05 \times 10^9 \)  | \( 9.58 \times 10^9 \)  | \( 1.48 \times 10^7 \)  |
| Sy.x          | 1699.2 | 4598.3   | 459.7    |
| AICc          | 711.2  | 436.8    | 584.7    |
| Prediction error | \( 7 \times 10^{11} \) | \( 3.8 \times 10^{12} \) | \( 502 689 \) |

*Because fit parameters were unable to be obtained for the Gompertz model for two countries, the statistical parameters were calculated from the remaining 26 countries (indicated by \( N = 26 \)). The generalised logistic model failed to adequately determine fit parameters in every case so is not included in this table. The prediction error is the mean difference between the prediction for the final day of the curve and the actual total number of cases for that day in each country.

Table 1. Average statistical fit parameters for the quadratic, simple square, simple exponential and Gompertz growth models for the early course of the epidemic in each country.
Fig. 2. The development of COVID-19 cases over time in 28 nations. The total number of cases as of 1 June 2020 is indicated by black circles while the early part of the curve is indicated by orange triangles. A quadratic fit curve based on the early part of the curve extrapolated into the future is shown as an orange dashed line. The first day of each fit curve is listed for each country. The black circles are obscured in those countries which had not begun to effectively reduce SARS-CoV-2 spread by 1 June 2020. The range of possible values corresponding to the 95% confidence interval around the predicted number of cases is indicated with dashed grey lines [58].
Results

A simple exponential growth model is a poor fit for the SARS-CoV-2 pandemic

The cumulative number of confirmed cases for the early portion of the epidemic in each of 28 countries was plotted with time and several model equations were fit to the early part of the data before the mitigating effects from public health policies arrested disease spread. We expect that changes in the trajectory of the cumulative number of cases over time would indicate the efficacy of these mitigation effects. In total, 20 (71%) countries showed an obvious change in the curvature of the trajectory of the total number of cases by 1 June 2020 (Fig. 2). When the early portion of the data (with an unchanged trajectory) was examined for all 28 countries, the Gompertz growth model had the best statistical fit (with an unchanged trajectory) was examined for all 28 countries (79%). This was also reflected in the average values of the AICc among all countries (Table 1). The mean standard error of the estimate (Sy.x, analogous to the root mean-squared error for fits of multiple parameters) value for the 28 countries was 1699 for the Gompertz model, 5613 for the quadratic model, 8572 for the simple square model and 11 257 for the exponential model (Table 1). Likewise, plots of the natural log of the total number of cases in the early parts of the epidemic (ln N) with time are significantly less linear (as determined by \( R^2 \)) than equivalent plots of the square root of the total number of cases (\( \sqrt{N} \)) (SI Table 2, SI Figs 1 and 2).

Quadratic growth models provide improved fits to the early portion of the epidemic courses

While logistic growth models have been widely used to model epidemics [26, 34, 35], uncertainties in estimates of \( R_0 \) (and therefore the population carrying capacity \( N_M \)) make modelling the epidemic difficult [24, 34]. (Fig. 4, Table 2, SI Table 3). For most countries, projection from the simple exponential model massively overpredicted the cumulative number of future cases. Projections generated more than 14 days prior to the final date suggested more than double the actual number of cases for 17 (61%) countries examined. In fact, for 15 (54%) countries, the exponential model gave at least one projection that differed from the eventual final day case number by a factor of greater than 10 000 fold, while the quadratic and simple square models made no final day overprediction by more than a factor of 3.3 and 2.1, respectively (i.e. using the first 10 days of data from Portugal projection using the exponential model projects 34 million cases while the quadratic, simple square and Gompertz growth models projects 24 957, 20 358 and 18 953 cases, respectively, while 23 683 total cases were actually observed on the final day). The total population of Portugal in 2018 was 10.3 million individuals. While logistic growth models project the number of daily cases (incidence) [18, 23], the actual number of cases for the final day was within the limits established by the 95% CI from the fit parameters was successfully predicted on average 63% of the time for all 28 countries when a 7-day prediction window was examined (Table 3).
Fig. 4. Comparison of the errors in final day prospective predictions for COVID-19 case numbers for different growth models for 28 countries for the simple exponential model (red triangles), the simple square model (green squares), the quadratic model (black circles), the Gompertz growth model (blue triangles) and the basic logistic growth model (purple diamonds). The first day of each fit curve is listed for each country. Note the log scale for the vertical axis which indicates the ratio of the predicted to observed number of cases. In each graph the fit values for each model using only data up to that day are used to predict the number of expected cases for the last day for which data are available (or the last day before significant curve deviation is observed; see Fig. 2). Days on which the fit was not statistically sound for the Gompertz model were omitted from the graph.
Projections using the quadratic and simple square models much more closely matched the observed final day case numbers. Only in four (14%) countries did the quadratic model ever overpredict the final number of cases by more than a factor of 2, while the simple square model overpredicted by a factor of 2 or greater for only one (4%) country (SI Table 3). For the quadratic model, the mean maximum daily overprediction was a factor of 1.6-fold (median 1.3-fold), while for the simple square model the mean maximum daily overprediction was 1.3-fold (median 1.1-fold). Both of these models produced much more accurate projections than the simple exponential model (Table 2). We also estimated the total accuracy of these simple models by assigning a binary success/failure score to predictions up to 60 days in advance for each day of the originally fit data and examining the width and bias towards over and underprediction for each model [36, 37] as well as using a simple scoring metric (Fig. 3). Both the quadratic and exponential models made fairly accurate predictions up to 10 days in advance, although the quality of forecasts from the exponential model quickly deteriorates further into the future and this is more obvious when the scoring metric is applied. The exponential model also produces much larger ranges of predictions within the 95% CI than the other models and quickly begins to significantly over predict the number of future total cases. Both the quadratic and exponential model tended to overpredict the number of future cases, while the simple square model tended to underpredict up to 10 days in advance but overpredict further into the future, while the Gompertz model generally underpredicted the total number of cases. Likewise, while all the models had a generalised expansion of their 95% CI prediction ranges more than 15 days in the future, this expansion was most significant for the exponential model.

Discussion

The start of the global SARS-CoV-2 pandemic has resulted in an unprecedented set of national responses. These responses have varied considerably from a strict lockdown in China [16], to aggressive contact tracing in South Korea [38], to mandatory shelter in place restrictions in France [39], to giving citizens information and allowing them more freedom to make choices in Sweden [40] and to other countries which appeared to be considering attempts to accelerate their progress towards herd immunity [41, 42]. The variety in these national prescriptions is a result of the different political and socioeconomic situations in individual countries which have to take into account not only the costs of these efforts both monetarily and in terms of lives, but also what can be reasonably achieved depending on the relationship between individual governments and their citizenry. Additionally, the spread of SARS-CoV-2 has been putatively linked to several inherent factors within a country, such as average population density [43], normal social behaviours [13] and even weather may have an effect [44]. The efficacy of similar prescriptions can also vary in pairs of neighbouring countries (i.e. the UK or Ireland). Therefore, it behooves every national government to review the results of its own policy prescriptions in order to make necessary course adjustments as quickly and accurately as possible.

While predictions about the future course of an epidemic, especially one as novel as COVID-19 are difficult under the best of circumstances, the severity of the pandemic has resulted in an unprecedented amount of epidemiological data being produced with daily frequency making it clear that the spread of cases is not well-modelled by simple exponential growth equations [17, 23, 45, 46]. This is not unprecedented as sub-exponential growth has been noted previously in a number of disease outbreaks [35, 47–49]. In fact, early observations of COVID-19 in China also observed sub-exponential growth rates for provinces other than Hubei (which had a more complex rate pattern) [50]. This point is further demonstrated by statistical analysis of, and the poor predictions made by the exponential model for the future number of cases as compared to the quadratic (parabolic) model [25]. However, the simple exponential model does not generate entirely terrible fit statistics in these countries (Table 1), and this may account for the conflation of the course of the pandemic with truly exponential growth. That the exponential growth constant term, k, is constantly decreasing after day 10 in 10 (68%) countries and generally decreasing overall in all but one country (SI Fig. 4) further indicates the overall utility of logistic models, which were explicitly developed to model the constantly decreasing rate of growth due to consumption of the available growth resource (i.e. the susceptible population pool of the SIR model) [26]. However, while logistic models are very good epidemic growth models [23, 31, 35], they are difficult to accurately fit during the early portion of a novel epidemic like COVID-19 due to inherent uncertainties in the mathematical shape parameters (Equation 1) of the curve itself and the population carrying capacity for SARS-CoV-2, Ntrinsic, which still has a significant uncertainty as the virus has only recently moved into the human population. The population carrying capacity for an epidemic (‘herd immunity’) is defined as 1–1/R0, and since current estimates for R0 vary from 1.5 to 6.5 [24] which implies that 33–85% of the population will need to have contracted the disease and developed immunity in order to terminate the epidemic (assuming a theoretical, static population with no new births or migration over the time course of the epidemic [20]). A discrepancy of this size will significantly affect projections based on logistic growth models.

Here we note the utility of the quadratic (parabolic) model to predict more than a month in advance the number of cases on an arbitrary final day using data from the early portion of a COVID-19 epidemic: here, early means up to when the total number of cases has reached about 40% of the population carrying capacity, or before the size of the infected epidemic growing at a logistic rate (Fig. 1), or before 8.9 × 10^{14} ± 4.7 × 10^{15} (5 × 10^{4})

### Table 2. Results of prospective predictions for total case load made using the various models for final day predictions

| Model               | Mean minimum normalised projection (observed/actual total cases) | Mean maximum normalised projection (observed/actual total cases) |
|---------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Simple exponential  | 1.11 ± 0.09 (1.14)                                           | 8.9 × 10^{14} ± 4.7 × 10^{15} (5 × 10^{4})                   |
| Quadratic (parabolic)| 0.25 ± 0.29 (0.09)                                           | 1.55 ± 0.64 (1.33)                                           |
| Simple square       | 0.42 ± 0.34 (0.24)                                           | 1.26 ± 0.35 (1.12)                                           |
| Gompertz growth     | 0.14 ± 0.24 (0.02)                                           | 3.8 × 10^{0} ± 2.0 × 10^{0} (2 × 10^{7})                     |

*All data given are mean results ± the sample standard error. Median values are given in parentheses.*
The Gompertz growth model, while often making largely correct projections often generates wildly inaccurate estimates of the population carrying capacity and both it and the generalised logistic model often simply fail to produce a statistically reliable result with the currently available data (i.e. the Gompertz model failed to completely fit all its parameters for any day of the total prediction for Denmark). Overestimation of the future number of cases may be problematic because the failure of the number of predicted cases to materialise could be erroneously used as evidence that poorly implemented and ineffective policy prescriptions are reducing the spread of SARS-CoV-2, which may lead to political pressure for premature cessation of all prescriptive measures and inevitably an increase in the number of cases and excess and unnecessary morbidities. Fortunately, projection using the quadratic model produces accurate, prospective predictions of the number of cases (Figs 3 and 4, Table 2) and despite being an exceedingly simple model performs relatively well in comparison to more complex models (Table 3, SI Table 4, SI Fig. 4, SI Appendix 2). The quadratic model does a fairly decent job in predicting the future number of cases up to 8 weeks in advance despite its simplicity. For five of the 8 weeks, its predictions are between the first and fourth quartile of the distribution of all the predictions for that week, better than 9 of the other 18 predictive models. The average percentage error for the predictions for the quadratic model was 30.2%, ranking it better than 8 of the other 18 predictive models. It should be noted that the performance of the quadratic model is likely more due to the fact that the COVID-19 epidemic in the United States was poorly controlled during that time period as this model is not able to predict when the current wave of the epidemic will end, but only how many cases can be expected if it is unaffected by the current set of public health interventions. In fact, the quadratic model is only capable of identifying the ebbing of an epidemic wave when it fails and we fully expect poor forecasts if there is a significant gap between waves such as occurred in the UK and Spain (SI Fig. 5). Advance knowledge of the expected number of COVID-19 cases is not without merit, however, and this method could readily serve as a baseline 'climatological forecast' for the early portion of future outbreaks [36].

One of the main benefits of the quadratic model is its simplicity as it is directly calculated using common spreadsheet programs and can be implemented without much difficulty or technical modelling expertise. In theory, this model can also be applied to smaller, sub-national populations, although the smaller number of total cases in these regions will undoubtedly give rise to larger statistical errors. And, of course, this analysis has focused on the early portion of the epidemics in these countries, colloquially referred to as the 'first wave'. More recent reporting has indicated that newer outbreaks of COVID-19 cases are occurring in countries that have already mitigated the original outbreak with appropriate, effective public and political behaviours, such as Spain, or those that have shown a second acceleration of the case trajectory without an apparent end to the initial outbreak, such as the United States and Poland (SI Fig. 5).

In no way does the empirical agreement between the quadratic model and empirical data negate the fact that the growth of the SARS-CoV-2 epidemic is logistic in nature in all 28 countries (Table 1, SI Table 1). We expect the suitability of these empirical quadratic fits is related to either the fact that quadratic form of the slope of the generalised logistic function allows an estimate to be made by extrapolation of tangents, or the limitation of the virus to a physical radius of infectivity around infectious individuals, or that it was still early in the pandemic and no country had yet officially logged even 1% of its population as having been infected, or all three [17, 18]. In fact, the simple existence of exposed, infected and removed populations in the SEIR model alone will reduce the size of the susceptible population (Equation 1) and reduce the rate

---

Table 3. Fraction of successful predictions of the incidence of new cases of COVID-19 using the quadratic model. The incidence (number of new cases per day) was calculated by subtracting the total number of cases on the previous day from the number of new cases per day calculated by subtracting the total number of cases on the previous day from the number of new cases on the current day. The fraction of successful predictions of the number of new cases for the final day and for total predictions (Figs 3 and 4, Table 2) was calculated by subtracting the total number of cases on the previous day from the total number of cases on the final day and dividing by the total number of cases on the final day. The results are given as the fraction of successful predictions. A prediction was judged to be successful if the total number of cases (actual) fell between the limit values of the predictions for that week, better than 9 of the other 18 predictive models. The average percentage error for the predictions for the quadratic model was 30.2%, ranking it better than 8 of the other 18 predictive models. It should be noted that the performance of the quadratic model is likely more due to the fact that the COVID-19 epidemic in the United States was poorly controlled during that time period as this model is not able to predict when the current wave of the epidemic will end, but only how many cases can be expected if it is unaffected by the current set of public health interventions. In fact, the quadratic model is only capable of identifying the ebbing of an epidemic wave when it fails and we fully expect poor forecasts if there is a significant gap between waves such as occurred in the UK and Spain (SI Fig. 5). Advance knowledge of the expected number of COVID-19 cases is not without merit, however, and this method could readily serve as a baseline 'climatological forecast' for the early portion of future outbreaks [36].

| Country | 5 day | 7 day | 12 day |
|---------|-------|-------|--------|
| Australia | 1.00 | 1.00 | 1.00 |
| Austria | 0.79 | 1.00 | 1.00 |
| Belgium | 0.48 | 0.48 | 0.56 |
| Brazil | 0.47 | 0.43 | 0.46 |
| Canada | 0.33 | 0.36 | 0.47 |
| China | 0.92 | 0.96 | 1.00 |
| Denmark | 0.87 | 0.90 | 1.00 |
| France | 0.54 | 0.67 | 0.82 |
| Germany | 0.49 | 0.66 | 0.80 |
| India | 0.46 | 0.46 | 0.52 |
| Iran | 0.35 | 0.36 | 0.36 |
| Ireland | 0.58 | 0.71 | 0.88 |
| Israel | 0.57 | 0.61 | 1.00 |
| Italy | 0.53 | 0.53 | 0.71 |
| Malaysia | 0.78 | 0.87 | 0.92 |
| Netherlands | 0.53 | 0.51 | 0.58 |
| Norway | 0.58 | 0.83 | 1.00 |
| Philippines | 0.41 | 0.48 | 0.66 |
| Poland | 0.45 | 0.45 | 0.52 |
| Portugal | 0.56 | 0.62 | 0.79 |
| Russia | 0.36 | 0.38 | 0.43 |
| South Korea | 1.00 | 1.00 | 1.00 |
| Spain | 0.71 | 0.76 | 1.00 |
| Sweden | 0.33 | 0.27 | 0.30 |
| Switzerland | 0.79 | 0.92 | 1.00 |
| Turkey | 0.68 | 0.72 | 0.96 |
| UK | 0.34 | 0.34 | 0.35 |
| USA | 0.31 | 0.32 | 0.35 |
| Mean = | 0.58 | 0.63 | 0.73 |
| Median = | 0.53 | 0.61 | 0.80 |
| Std. dev. = | 0.21 | 0.24 | 0.26 |

Results are given as the fraction of successful predictions. A prediction was judged to be successful if the total number of cases (actual) fell between the limit values of the prediction using the totals generated by the 95% CI from the fit parameters using the sum of predictions with 5, 7 and 12 day intervals calculated for all possible intervals for each country using the same days as from the regular quadratic model fits (Fig. 2).
of transmission due to either the overall reduction of the population capable of being infected or due to local depletion in an imperfectly mixed real-world epidemic [18]. Because this method is focused on the rate of case growth over time certain caveats are worth noting. First, the true number of COVID-19 cases is a matter of debate as there is speculation that a significant fraction of infections are not being identified [23, 51, 52]. While this implies that the true number of COVID-19 cases is higher than confirmed cases, the true number of cases is highly unlikely to be significantly smaller than the reported count meaning the confirmed case count is close to a minimum estimate of the true number of cases. Second, the undercounting rate is likely variable, especially during periods of intense case increases and due to the significant number of asymptomatic cases [5, 52]. Third, because this method utilises cumulative cases counts, errors in measurement will propagate over time [18]. While these factors are not insignificant, it is important to remember here that this method is a simple fitting of a derivative tangent to a curve and we do not purport a clear relationship between the determined empirical fit parameters and fundamental properties of the virus.

Instead, we are explicitly fitting our models to growth in the empirically determined confirmed case number. While this is related to a number of other important public health metrics such as the case fatality rate, the infection fatality rate and hospital usage statistics, other factors which are not inherent to the virus, such as economic factors and population demographics also influence these metrics [32, 39, 40, 53–55]. Furthermore, the confirmed case numbers are at best a minimum count of the total number of infections which is undoubtedly higher given imperfect detection methods and not insignificant number of asymptomatic cases of COVID-19 reported [4, 18, 20, 23, 34, 51, 52, 56]. Here we sought to find a simple model that could be widely employed to identify how many confirmed cases would be expected in the near future. The continuation of the epidemic in some countries despite the decrease in the average number of new cases per day suggests that the quadratic tangent model could be a better model of the future case load (SI Fig. 5). Here we largely focus on the quadratic model rather than the simple square model for the previously mentioned reasons, we must also note that quadratic curve fitting is natively implemented in most common spreadsheet software while the simple square model is often not. By monitoring the $R^2$ values for the quadratic models, it is a simple task to identify when the current wave of the epidemic is beginning to subside within a country (i.e. ‘bending the curve’). Using this metric we can define the waves by a string of days during which the cumulative confirmed COVID-19 case count is increasing at a quadratic rate; the wave ends when number of cumulative cases no longer follows this quadratic rate. We recommend the use of an empirical $R^2$ value of 0.985 for identifying when the rate of infection is beginning to subside, but more conservative estimates can also be made by lowering this threshold. This does not preclude using AIC as an alternative metric, although conservative estimates can also be made by lowering this threshold.

Examination of the data collected here suggests that early, aggressive early measures have been most effective at reducing disease burden within a country. Countries that initially adopted less stringent measures (such as the US, UK, Russia and Brazil) are currently more heavily burdened than those countries that started with more intense prescriptions (such as China, South Korea, Australia, Denmark and Vietnam) [57]. Poland, had very few cases in the spring of 2020 when it enacted a strict lockdown, but many cases in that autumn after restrictions were eased. On the other hand, Vietnam which took early aggressive action against viral spread [7, 57] did not have a large enough case load to be noted or analysed here. The effectiveness of aggressive measures may be due to the apparent quadratic rate of growth of total cases with time (Equation 2); while growth in proportion to the square of the number of days is fast, it is not as fast as exponential growth. Early reductions in the number of infected individuals and the number of interactions they have with susceptible individuals clearly pays compounded dividends in future case reductions as advantage can be taken of this slower spreading rate.

Conclusions

Quadratic modelling of the cumulative number of COVID-19 cases within national boundaries is a simple and effective model for the growth in the total number of cases of COVID-19. This empirical observation can obviate the difficulty in estimating the effect of human behaviours on these predictions and instead focus on the available data. Until vaccines can be fully distributed, social distancing, contact tracing and other aggressive quarantine measures are the most effective tools to combat the spread of SARS-CoV-2 and it is imperative to monitor whether these measures are being effectively implemented for this and future epidemics. Accurate modelling of the future number of cases within countries will help to minimise the social costs and financial burdens of these necessary mitigation measures.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0950268821000649.

Acknowledgements. We thank Dr Marcin Ziemniak for useful discussions.

Financial support. The work was supported by the National Science Centre, Poland (grant agreement 2014/15/D/NZ1/00968 to M.W.G.) and the EMBO Installation Grant, European Molecular Biology Organization to M.W.G.

Conflicts of interest. None.

Data availability. Datasets of the original ECDC data and the curve fits are available on the Zenodo repository at http://doi.org/10.5281/zenodo.4454173

References

1. Organization WH. (2020) Coronavirus disease 2019 (COVID-19) Situation Report – 51. Available at https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10: World Health Organization.
2. Sun J et al. (2020) COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends in Molecular Medicine 26, 483–495.
3. Rothen HA and Byrareddy SN (2020) The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity 109, 102433.
4. Mizumoto K et al. (2020) Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. European Communicable Disease Bulletin 25, 1–5.
5. Nishiura H et al. (2020) Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). International Journal of Infectious Diseases 94, 154–155.
6. (2020) Website. Available at https://coronavirus.jhu.edu/map.html. In.
7. Cowling BJ et al. (2020) Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. The Lancet Public Health 5, e279–e288.
8. Thanh Le T et al. (2020) The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery 19, 305–306.
10

9. Cohen J (2020) "Incredible milestone for science.” Pfizer and BioNTech update their promising COVID-19 vaccine result. Science. doi:10.1126/science.abi7754.

10. Ramasamy MN et al. (2021) Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 396, 1979–1993.

11. Covid-19 National Emergency Response Center E CMTK (2020) Prevention. Contact transmission of COVID-19 in South Korea: novel investigation techniques for tracing contacts. Osong Public Health and Research Perspectives 11, 60–63.

12. Koo JR et al. (2020) Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. The Lancet Infectious Diseases 20, 678–688.

13. Bavel JF et al. (2020) Using social and behavioural science to support COVID-19 pandemic response. Nature Human Behaviour 4, 460–471.

14. Group IRC (2021) Dexamethasone in hospitalized patients with COVID-19 – preliminary report. The New England Journal of Medicine 384, 693–704.

15. Bloch EM et al. (2020) Deployment of convoyal plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation 130, 2757–2765.

16. Roosa K et al. (2020) Real-time forecasts of the COVID-19 epidemic in China from February 5th to February 24th, 2020. Infectious Disease Modelling 5, 256–263.

17. Ziff RL and Ziff RM (2020) Fractal kinetics of COVID-19 pandemic (with update 3/1/20). medRxiv preprint. Available at https://www.medrxiv.org/content/10.1101/2020.02.16.20023820v2.

18. King AA et al. (2015) Avoidable errors in the modelling of outbreaks of emerging pathogens, with special reference to Ebola. Proceedings of the Royal Society B-Biological Sciences 282, 20150347.

19. Toulousia A (2001) Analysis of logistic growth models. Research Letters in the Information and Mathematical Sciences 2, 23–46.

20. Coby S (2020) Modeling infectious disease dynamics. Science 368, 713–714.

21. Anderson RM and May RM (1985) Herd-Immunity to helminth infection and implications for parasite control. Nature 315, 493–496.

22. Fine P, Eames K and Heymann DL (2011) "Herd immunity": a rough guide. Clinical Infectious Diseases 52, 911–916.

23. Ma JL et al. (2014) Estimating initial epidemic growth rates. Bulletin of Mathematical Biology 76, 245–260.

24. Liu Y et al. (2020) The reproductive number of COVID-19 is higher compared to SARS coronavirus. Journal of Travel Medicine 27, taa027.

25. Brandenburg A (2020) Piecewise quadratic growth during the 2019 novel coronavirus epidemic. Infectious Disease Modelling 5, 681–690.

26. Tjorne KMC and Tjorne E (2017) The use of Gompertz models in growth analyses, and new Gompertz-model approach: an addition to the unified-Richards family. Public Library of Science One 12, e0176961.

27. Laird AK (1964) Dynamics of tumor growth. British Journal of Cancer 13, 490–502.

28. Vora A, Burke DS and Cummings DAT (2008) The impact of a physical geographic barrier on the dynamics of measles. Epidemiology and Infection 136, 713–720.

29. Kupersmidt K and Cohen J (2020) Can China’s COVID-19 strategy work elsewhere? Science 367, 1061–1062.

30. Maier BF and Brockmann D (2020) Effective containment explains sub-national COVID-19 cases and infections. BioMed Central Medicine 18, 332.

31. Yang W et al. (2020) Rational evaluation of various epidemic models based on the COVID-19 data of China. medRxiv preprint. Available at https://www.medrxiv.org/content/10.1101/2020.03.12.20034595v1.

32. Friedman J et al. (2020) Predictive performance of international COVID-19 mortality forecasting models. medRxiv preprint. Available at https://www.medrxiv.org/content/10.1101/2020.07.15.20151233v5.

33. (2020) Website, Control ECIPa. Available at https://www.ecdc.europa.eu/en/publications-data/download-todays-data-geographic-distribution-coronavirus-c19-cases-worldwide: European Centre for Disease Prevention and Control.

34. Liu W, Tang S and Xiao Y (2015) Model selection and evaluation based on emerging infectious disease data sets including A/H1N1 and ebola. Computational and Mathematical Methods in Medicine 2015, 207105.

35. Viboud C, Simonsen L and Chowell G (2016) A generalized-growth model to characterize the early ascending phase of infectious disease outbreaks. Epidemics 15, 27–37.

36. Gneiting T and Raftery AE (2007) Strictly proper scoring rules, prediction, and estimation. Journal of the American Statistical Association 102, 359–378.

37. Funk S et al. (2019) Assessing the performance of real-time epidemic forecasts: a case study of ebola in the Western area region of Sierra Leone, 2014–15. Public Library of Science Computational Biology 15(2), e1006785.

38. Oh J et al. (2020) National response to COVID-19 in the Republic of Korea and lessons learned for other countries. Health Systems and Reform 6, e1753464.

39. Motati J-P (2020) The French response to COVID-19: intrinsic difficulties at the interface of science, public health, and policy. Lancet Public Health 5, e255.

40. Sjodin H et al. (2020) COVID-19 healthcare demand and mortality in Sweden in response to non-pharmaceutical mitigation and suppression scenarios. International Journal of Epidemiology 49, 1443–1453.

41. Alltman DM, Douek DC and Boyton RJ (2020) What policy makers need to know about COVID-19 protective immunity. Lancet 395, 1527–1529.

42. Vogel G (2020) Sweden’s gamble. Science 370, 159–163.

43. Rocklov J and Sjödin H (2020) High population densities catalysate the spread of COVID-19. Journal of Travel Medicine 27, taa038.

44. Wang J et al. (2020) Impact of temperature and relative humidity on the transmission of COVID-19: a modeling study in China and the United States. BMJ Open 11, e043863.

45. Lee SY, Lei BW and Mallick B (2020) Estimation of COVID-19 spread curves integrating global data and borrowing information. Public Library of Science One 15, e0236860.

46. Fukui M and Furukawa C (2020) Power Laws in Superspreading Events: Evidence from Coronavirus Outbreaks and Implications for SIR Models. medRxiv preprint. Available at https://www.medrxiv.org/content/10.1101/2020.06.11.20128058v2.

47. Chowell G et al. (2016) Mathematical models to characterize early epidemic growth: a review. Physics of Life Reviews 18, 66–97.

48. Santermans E et al. (2016) Spatiotemporal evolution of ebola virus disease at sub-national level during the 2014 West Africa epidemic: model scrutiny and data meagerness. Public Library of Science One 11(1), e0147172.

49. Colgate SA et al. (1989) Risk behavior-based model of the cubic growth of acquired immunodeficiency syndrome in the United States. Proceedings of the National Academy of Sciences of the United States of America 86, 4793–4797.

50. Muniz-Rodriguez K et al. (2020) Doubling time of the COVID-19 epidemic by province, China. Emerging Infectious Diseases 26, 1912–1914.

51. Li R et al. (2020) Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 368, 489–493.

52. Russell TW et al. (2020) Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections. BioMed Central Medicine 18, 332.

53. Meyerowitz-Katz G and Merone L (2020) A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. International Journal of Infectious Diseases 101, 138–148.

54. Baud D et al. (2020) Real estimates of mortality following COVID-19 infection. The Lancet Infectious Diseases 20(7), 773.

55. Guan W-J et al. (2020) Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. The European Respiratory Journal 55, 2000547.

56. Held L, Meyer S and Bracher J (2017) Probabilistic forecasting in infectious disease epidemiology: the 13th armitage lecture. Statistics in Medicine 36, 3443–3460.

57. Gibney E (2020) Whose coronavirus strategy worked best? Scientists hunt most effective policies. Nature 581, 15–16.

58. Colilla S et al. (2013) Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population. American Journal of Cardiology 112, 1142–1147.

https://doi.org/10.1017/S0950268821000649 Published online by Cambridge University Press